LOS ANGELES, CA / ACCESSWIRE / March 20, 2017 / Vitality Biopharma, Inc. (OTCQB: VBIO) ("Vitality" or the "Company"), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, will be presenting at this year's MicroCap Conference on April 4th in New York City at the Essex House.

The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks, and is sponsored by The Special Equities Group and Maxim Group. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various expert panels, and mingle with other investors. For the most updated list of companies, please visit the conference website (http://microcapconf.com/conferences/new-york-2017/).

Vitality Biopharma will be presenting on Tuesday, April 4th, at 10:00am EDT. Conference registration will begin on Tuesday, April 4th, at 7:00am, and the event ends with a reception in the evening. The day will be jam-packed with company presentations, one-on-one meetings, and networking. This event is restricted to only portfolio managers, analysts, and private investors. To register, please visit the conference website (www.microcapconf.com).

News Compliments of ACCESSWIRE.

About Vitality Biopharma (OTCQB: VBIO)

Vitality Biopharma is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. For more information, visit: www.vitality.bio. Follow us on Facebook, Twitter, and LinkedIn.

Notice Regarding Forward-Looking Statements

This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the United States Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations, and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

Contact:

Vitality Biopharma
Investor Relations
info@vitality.bio
1-530-231-7800
www.vitality.bio

SOURCE: Vitality Biopharma, Inc.